Company Technology Collagenesis is an innovative biomaterials company focused on the development, processing, and marketing of advanced tissue-based products and applications. The company's core competency is its Human Tissue Collagen Matrix (HTCM), which can separate intact human collagen fibers, proteoglycans, and elastic network into an injectable form. The resulting injectable HTCM implant has potential applications in soft tissue augmentation, drug delivery, orthopedics, ophthalmology, and medical device coating. The 30,000-sq. ft. state-of-the-art facility located in Beverly, Massachusetts includes class 10,000 clean rooms. The company currently has 85 employees and since 1995, has invested more than $35 million in developing its human tissue matrix products. Products The company's first generation of products is derived from autologous HTCM. The company's present commercial products include Autologen® for soft tissue augmentation for treating facial contour defects; BioBank®, a unique tissue-storage service; and Vocalogen®, for treatment of vocal cord augmentation. The company has developed a second generation of products, which include Dermalogen® and Urologen®, which are off-the-shelf allogeneic implants. Dermalogen® is now available for treatment of facial contour defects and Urologen™ is in clinical trials for treatment of female urinary incontinence. The company has also recently announced an agreement with C. R. Bard. This major urology company is distributing DuraDerm™ an acellular allograft, processed for them by Collagenesis. DuraDerm™ Allograft is intended for use in the repair of damages or inadequate soft tissue. 1 Patents The company holds 21 patents on its technology. Please send your resume to: hrcollagenesis@hotmail.com For more information please visit us at: http://www.collagenesis.com
Location:
|